abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
Published 7 years ago • 471 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
4:34
card: cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
4:06
combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
1:19
comparing abiraterone and docetaxel in prostate cancer treatment
-
1:32
dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
5:46
metastatic castration-resistant prostate cancer – new learnings and perspectives
-
1:34
dr. chi on abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer
-
2:12
abiraterone for metastatic, hormone sensitive, prostate cancer
-
6:10
emerging management of metastatic castration-sensitive prostate cancer: front-line chemotherapy ...
-
1:30
bmi and clinical outcomes in patients with metastatic castration-resistant prostate cancer
-
0:45
dr. hahn on patients with prostate cancer whom neither docetaxel or abiraterone is an option
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
4:46
quality of life and new therapeutic options for metastatic castration-resistant prostate cancer
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
5:59
apalutamide in combination with abiraterone acetate, docetaxel and prednisone for mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
2:31
dr. tagawa on abiraterone and docetaxel in mcrpc